ReviewNeuropsychiatric disease and treatment2025
Maternal Immune Activation and Neurodevelopmental Disorders: Integrating Molecular, Cellular and Systems Mechanisms.
Review in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Immune and Autoimmune Mechanisms in Autism Spectrum Disorder: Linking Molecular Pathways to Neuropsychological Trajectories Across the Lifespan.International journal of molecular sciences · 2026Review
- Cytokines in First-Episode Psychosis: Implications for Pathophysiology: A Narrative Literature Review.Brain sciences · 2026Review
- Toward a Unified Neuroimmune Framework for Infection-Associated Psychiatric Disorders.Diseases (Basel, Switzerland) · 2026Review
- Fibrinogen as a Driver of Oxidative Stress and Apoptosis in the Fetal Brain After Maternal Influenza.Research square · 2026Article
- A Developmental Neuroimmune Cascade Model of Autism Spectrum Disorder.International journal of molecular sciences · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodevelopmental Disorders (NDDs) represent chronic cerebral dysfunctions arising from gene-environment interactions, encompassing conditions such Autism Spectrum Disorders (ASD) and attention-deficit/hyperactivity disorders (ADHD). Emerging evidence identifies Maternal immune activation (MIA) as a critical environmental risk factor for NDDs. Gestational infections, inflammatory responses, or immune dysregulation elevate maternal-fetal inflammatory mediators, which disrupt neurodevelopmental trajectories via placental-fetal signaling cascades. Preclinical models (rodents, non-human primates) demonstrate that MIA induces characteristic NDD phenotypes-including social deficits and cognitive impairments-through microglial hyperactivation, aberrant synaptic pruning, oxidative stress, and mitochondrial dysfunction. Concurrently, gut microbiota dysbiosis and Th17/Treg immune imbalance exacerbate neuroinflammatory processes. Novel therapeutic strategies targeting inflammatory pathways microglial modulation, or microbial homeostasis restoration show translational promise. Future investigations must unravel MIA's molecular underpinnings and multifactorial interactions to enable early-risk stratification and precision interventions for NDDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.